Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy

European Journal of Surgical Oncology

Volumn 40, Issue 12, 2014, Pages 1724-1730

  Rouanne, M ^a,b   Girma, A ^a   Neuzillet, Y ^a,b   Vilain, D ^a   Radulescu, C ^a   Letang, N ^a   Yonneau, L ^a   Herve J M ^a   Botto, H ^a   Le Stanc, E ^a   Lebret, T ^a,b  

^a FOCH HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

18FDG PET ACTY; Muscle invasive bladder cancer; Neoadjuvant chemotherapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYSTECTOMY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROMETASTASIS; PATIENT SELECTION; PELVIS LYMPH NODE; PET-CT SCANNER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ADJUVANT THERAPY; ADULT; AGED; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC USE; LYMPH NODE; MIDDLE AGED; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; URINARY BLADDER NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CONTRAST MEDIA; CYSTECTOMY; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIMODAL IMAGING; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS;

EID: 84920654857     PISSN: 07487983     EISSN: 15322157     Source Type: Journal    
DOI: 10.1016/j.ejso.2014.08.479     Document Type: Article

References (29)

1. J.J. Meeks, J. Bellmunt, and B.H. Bochner A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer Eur Urol 62 3 2012 523 533
2. A. Feifer, J.M. Taylor, and M. Shouery Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder J Clin Oncol 29 Suppl 7 2011
3. S. Madersbacher, H. Hochreiter, and H. Burkhard Radical cystectomy for bladder cancer today - a homogeneous series without neoadjuvant therapy J Clin Oncol 21 2003 690 696
4. R.E. Hautmann, R.C. de Petriconi, and C. Pfeiffer Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients Eur Urol 61 2012 1039 1047
5. G. Niegisch, A. Lorch, and M.J. Droller Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit? Eur Urol 64 3 2013 355 357
6. T. Jones, and P. Price Development and experimental medicine applications of PET in oncology: a historical perspective Lancet Oncol 13 2012 e116 e125
7. S.H. Culp, R.J. Dickstein, and H.B. Grossman Refining patient selection for neoadjuvant chemotherapy before radical cystectomy J Urol 191 2014 40 47
8. A. Stenzl, N.C. Cowan, and M. De Santis Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines Eur Urol 59 2013 1009 1018
9. M.L. Paik, M.J. Scolieri, and S.L. Brown Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy J Urol 163 2000 1693 1696
10. J.E. Husband Computer tomography and magnetic resonance imaging in the evaluation of bladder cancer J Belge Radiol 78 1995 350 355
11. V. Kundra, and P.M. Silverman Imaging in oncology from the University of Texas M.D. Anderson Cancer Center: imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder Am J Roentgenol 180 2003 1045 1054
12. H.1 Goodfellow, Z. Viney, and P. Hughes Role of Fdg PET/CT in the staging of bladder cancer BJU Int 114 3 2014 Sep 389 395
13. M.1 Hitier-Berthault, C. Ansquer, and J. Branchereau 18 F-fluorodeoxyglucose positron emission tomography-computed tomography for preoperative lymph node staging in patients undergoing radical cystectomy for bladder cancer: a prospective study Int J Urol 20 8 2013 788 796
14. T. Maurer, M. Souvatzoglou, and H. Kübler Diagnostic efficacy of [11C] choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy Eur Urol 61 5 2012 1031 1038
15. T.K. Jensen, P. Holt, and O. Gerke Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology Scand J Urol Nephrol 45 2011 122 128
16. M. Lodde, L. Lacombe, and J. Friede Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma BJUInt 106 2010 658 663
17. G. Swinnen, A. Maes, and H. Pottel FDG PET/CT for the preoperative lymph node staging of invasive bladder cancer Eur Urol 57 2010 641 647
18. A.S. Kibel, F. Dehdashti, and M.D. Katz Prospective study of [18F] fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma J Clin Oncol 10 27 2009 4314 4320
19. O. Drieskens, R. Oyen, and H. Van Poppel FDG PET for preoperative staging of bladder cancer Eur J Nucl Med Mol Imaging 32 2005 1412 1417 [15]
20. M. Orevi, M. Klein, and E. Mishani 11C-acetate PET/CT in bladder urothelial carcinoma: intraindividual comparison with 11C-choline Clin Nucl Med 37 4 2012 e67 e72
21. L.S. Mertens, A. Fioole-Bruining, and E. Vegt Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle BJU Int 112 6 2013 729 734
22. H.B. Grossman, R.B. Natale, and C.M. Tangen Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer N Engl J Med 349 2003 859
23. J. Bellmunt, A. Ribas, and J. Albanell M-CAVI, a neoadjuvant carboplatin-based regimen for the treatment of T2-4N0M0 carcinoma of the bladder Am J Clin Oncol 19 1996 344
24. R. Rosenblatt, A. Sherif, and E. Rintala Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer Eur Urol 61 2012 1229
25. L.S. Mertens, A. Fioole-Bruining, and B.W. van Rhijn FDG-positron emission tomography/computerized tomography for monitoring the response of pelvic lymph node metastasis to neoadjuvant chemotherapy for bladder cancer J Urol 189 5 2013 1687 1691
26. G. Griffiths, R. Hall, and R. Sylvester International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial J Clin Oncol 29 2011 2171 2177
27. P.U. Malmstrom, E. Rintala, and R. Wahlqvist Five-year follow-up of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group J Urol 155 1996 1903 1906
28. International Collaboration of Trialists Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial Lancet 354 1999 533 540
29. L.S. Mertens, M.C. Mir, and A.M. Scott (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer Urology 83 2 2014 393 399